Hedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulness

Treatment of locally advanced basal cell carcinomas (laBCCs) with large, aggressive, destructive, and disfiguring tumors, or metastatic disease is challenging. Dysregulation of the Hedgehog (Hh) signaling pathway has been identified in the vast majority of basal cell carcinomas (BCCs). There are two...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic Advances in Medical Oncology 2016-09, Vol.8 (5), p.375-382
Main Authors: Silapunt, Sirunya, Chen, Leon, Migden, Michael R.
Format: Article
Language:English
Subjects:
Alopecia
Antitumor activity
Basal cell carcinoma
Body weight loss
Carcinoma
Hedgehog protein
Kinases
Metastases
Nausea
Reviews
Signal transduction
Skin cancer
Taste disorders
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment of locally advanced basal cell carcinomas (laBCCs) with large, aggressive, destructive, and disfiguring tumors, or metastatic disease is challenging. Dysregulation of the Hedgehog (Hh) signaling pathway has been identified in the vast majority of basal cell carcinomas (BCCs). There are two United States Food and Drug Administration (US FDA)-approved Hh pathway inhibitors (HPIs) that exhibit antitumor activity in advanced BCC with an acceptable safety profile. Common adverse effects include muscle spasms, dysgeusia, alopecia, fatigue, nausea and weight loss.
ISSN:1758-8340
1758-8359
1758-8359
DOI:10.1177/1758834016653605